Fig. 2: Novel DDI199 compound inhibits target genes.
From: Generation and validation of a novel multitarget small molecule in glioblastoma
A Schematic representation of the structural origin of novel DDI199 compound. B Physicochemical characteristics of DDI199. MW: molecular weight (g/mol); logP: log octanol/water partition coefficient; nON: number of Hydrogen acceptors; nOHNH: number of Hydrogen donors; BBB (+/-): blood-brain barrier permeability where + and – represents molecule cross or not the BBB. C IC50 values of DDI199 for HDAC1 and HDAC6. D-F Representative western blot of HDAC6 and HDAC1 and their targets acetyl α-tubulin and acetyl H3 in (D-E) U87-MG and (F) GNS166 cells cultured with DDI199, SAHA and Tubastatin A (TUB A) (n = 3). G Representative western blot of Acetylated-Lysine in U87-MG and GNS166 cells cultured with indicated concentrations of DDI199 and SAHA (n = 2). H, I MAO-A and MAO-B inhibitory capacity of DDI199 and reference compounds Clorgiline Selegiline and Rasalgiline. J IC50 values of indicated compounds as MAO-B inhibitors. K, L AChE and BChE inhibitory capacity of DDI199 and reference compounds Donepezil and Rivastigmine. M IC50 values of indicated compounds as BChE inhibitors.
